Cencora Inc. (COR)vsEDAP TMS SA (EDAP)
COR
Cencora Inc.
$275.04
-0.10%
HEALTHCARE · Cap: $51.53B
EDAP
EDAP TMS SA
$4.31
+0.23%
HEALTHCARE · Cap: $156.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 443630% more annual revenue ($328.68B vs $74.07M). COR leads profitability with a 0.8% profit margin vs -41.7%. COR appears more attractively valued with a PEG of 0.56. COR earns a higher WallStSmart Score of 64/100 (C+).
COR
Buy64
out of 100
Grade: C+
EDAP
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.3%
Fair Value
$180.05
Current Price
$275.04
$94.99 premium
Margin of Safety
+41.7%
Fair Value
$8.41
Current Price
$4.31
$4.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 75 in profit
Earnings expanding 128.3% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 1.2B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 15.8x book value
3.8% revenue growth
0.8% margin — thin
Operating margin of 1.7%
Trading at 8.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -124.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, EPS Growth, Altman Z-Score. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : EDAP
Revenue growth of 13.9% demonstrates continued momentum.
Bear Case : COR
The primary concerns for COR are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 3.65 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Bear Case : EDAP
The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.
Key Dynamics to Monitor
COR profiles as a value stock while EDAP is a turnaround play — different risk/reward profiles.
COR carries more volatility with a beta of 0.65 — expect wider price swings.
EDAP is growing revenue faster at 13.9% — sustainability is the question.
COR generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
COR scores higher overall (64/100 vs 25/100). EDAP offers better value entry with a 41.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
EDAP TMS SA
HEALTHCARE · MEDICAL DISTRIBUTION · USA
EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?